DR. KOTARO SASAKI, M.D.
Student, Health Care at Terrace St, Pittsburgh, PA
License number
Pennsylvania MT193660
Category
Student, Health Care
Type
Student in an Organized Health Care Education/Training Program
Address
Address
A711 Terrace St, Pittsburgh, PA 15261
Phone
(412) 802-6013
(412) 802-6079 (Fax)
(412) 606-5763
(412) 802-6079 (Fax)
(412) 606-5763
Professional information
Dr. Kotaro Sasaki, Pittsburgh PA - MD (Doctor of Medicine)
Specialties:
Anatomic Pathology
Address:
A711 Scaife Hl, Pittsburgh 15261
(412) 802-6013 (Phone), (412) 802-6079 (Fax)
(412) 802-6013 (Phone), (412) 802-6079 (Fax)
Certifications:
Anatomic Pathology, 2011
Awards:
Healthgrades Honor Roll
Languages:
English
Th1-Associated Micrornas And Their Use For Tumor Immunotherapy
US Patent:
2013034, Dec 26, 2013
Filed:
Jun 18, 2013
Appl. No.:
13/920357
Inventors:
Gary Kohanbash - Pittsburgh PA, US
Kotaro Sasaki - Pittsburgh PA, US
Kotaro Sasaki - Pittsburgh PA, US
International Classification:
A61K 35/14
US Classification:
424 9321
Abstract:
Described herein is the identification of miRNAs (miRs) that are up-regulated in Th1 cells compared to Th2 cells (referred to herein as Th1-associated miRs). In particular, the miR-17-92 gene cluster was found to exhibit significantly greater expression in Th1 cells. Over-expression of miR-17-92 in T cells promotes the Th1 phenotype. Thus, the use of Th1-associated miRs for cancer immunotherapy is described. Provided herein are isolated T cells containing a heterologous nucleic acid molecule encoding a Th1-associated miR, such as the miR17-92 gene cluster, or a portion thereof. Further provided is a method of treating cancer in a subject by administering to the subject an isolated T cell as disclosed herein. Also provided is a method of treating a subject with cancer by transfecting isolated T cells obtained from the subject with a heterologous nucleic acid molecule encoding a Th1-associated miR and administering the transfected T cells to the subject.
Th1-Associated Micrornas And Their Use For Tumor Immunotherapy
US Patent:
8486911, Jul 16, 2013
Filed:
Aug 7, 2012
Appl. No.:
13/568457
Inventors:
Hideho Okada - Pittsburgh PA, US
Gary Kohanbash - Pittsburgh PA, US
Kotaro Sasaki - Pittsburgh PA, US
Gary Kohanbash - Pittsburgh PA, US
Kotaro Sasaki - Pittsburgh PA, US
Assignee:
University of Pittsburgh—Of the Commonwealth System of Higher Education - Pittsburgh PA
International Classification:
A01N 43/04, A61K 31/70
US Classification:
514 44A, 514 44 R
Abstract:
Described herein is the identification of miRNAs (miRs) that are up-regulated in Th1 cells compared to Th2 cells (referred to herein as Th1-associated miRs). In particular, the miR-17-92 gene cluster was found to exhibit significantly greater expression in Th1 cells. Over-expression of miR-17-92 in T cells promotes the Th1 phenotype. Thus, the use of Th1-associated miRs for cancer immunotherapy is described. Provided herein are isolated T cells containing a heterologous nucleic acid molecule encoding a Th1-associated miR, such as the miR17-92 gene cluster, or a portion thereof. Further provided is a method of treating cancer in a subject by administering to the subject an isolated T cell as disclosed herein. Also provided is a method of treating a subject with cancer by transfecting isolated T cells obtained from the subject with a heterologous nucleic acid molecule encoding a Th1-associated miR and administering the transfected T cells to the subject.
Th1-Associated Micrornas And Their Use For Tumor Immunotherapy
US Patent:
2010032, Dec 23, 2010
Filed:
Jun 17, 2010
Appl. No.:
12/818016
Inventors:
Hideho Okada - Pittsburgh PA, US
Gary Kohanbash - Pittsburgh PA, US
Kotaro Sasaki - Pittsburgh PA, US
Gary Kohanbash - Pittsburgh PA, US
Kotaro Sasaki - Pittsburgh PA, US
International Classification:
A61K 35/12, C12N 5/0783, A61P 35/00
US Classification:
424 9321, 435325
Abstract:
Described herein is the identification of miRNAs (miRs) that are up-regulated in Th1 cells compared to Th2 cells (referred to herein as Th1-associated miRs). In particular, the miR-17-92 gene cluster was found to exhibit significantly greater expression in Th1 cells. Over-expression of miR-17-92 in T cells promotes the Th1 phenotype. Thus, the use of Th1-associated miRs for cancer immunotherapy is described. Provided herein are isolated T cells containing a heterologous nucleic acid molecule encoding a Th1-associated miR, such as the miR17-92 gene cluster, or a portion thereof. In some embodiments, the T cell is a tumor antigen (TA)-specific T cell, such as a TA-specific CTL. Further provided is a method of treating cancer in a subject by selecting a subject with cancer and administering to the subject an isolated T cell as disclosed herein. Also provided is a method of treating a subject with cancer by transfecting isolated T cells obtained from the subject with a heterologous nucleic acid molecule encoding a Th1-associated miR and administering the transfected T cells to the subject. In some embodiments of the method, the heterologous nucleic acid molecule encodes the miR-17-92 transcript or a portion thereof. In some embodiments, the isolated T cell is a TA-specific T cell, such as a CTL.